Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in autoimmune benign hematological disorders
NCT05086744Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of Iptacopan in immune thrombocytopenia (ITP), cold agglutinin disease (CAD), sponsored by Novartis. Started Dec 2021; status: terminated.
02
Drugs
Iptacopan
03
Conditions
immune thrombocytopenia (ITP)cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT05086744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086744.